人源化暴露头孢吡肟、厄他培南和左氧氟沙星对产超广谱β-内酰胺酶大肠埃希菌在复杂性尿路感染小鼠模型中的转化功效。
Translational Efficacy of Humanized Exposures of Cefepime, Ertapenem, and Levofloxacin against Extended-Spectrum-β-Lactamase-Producing Escherichia coli in a Murine Model of Complicated Urinary Tract Infection.
机构信息
Center for Anti-infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.
Center for Anti-infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA
出版信息
Antimicrob Agents Chemother. 2017 Oct 24;61(11). doi: 10.1128/AAC.01329-17. Print 2017 Nov.
Abstract
Validated animal models are required as bridging tools to assess the utility of novel therapies and potential microbiologic outcomes. Herein, we utilized uropathogenic extended-spectrum-β-lactamase (ESBL)-producing and non-ESBL-producing in the neutropenic murine complicated urinary tract infection (cUTI) model with humanized exposures of cefepime, ertapenem, and levofloxacin to assess its translational value to human outcomes. Our data support the translational utility of this murine model to cUTI in humans as humanized exposures produced microbiologic outcomes consistent with the phenotypic profiles of the organisms.
摘要
需要经过验证的动物模型作为桥梁工具，以评估新型疗法和潜在微生物学结果的效用。在此，我们利用产超广谱β-内酰胺酶（ESBL）和非产 ESBL 的 在中性粒细胞减少的鼠复杂性尿路感染（cUTI）模型中，进行了头孢吡肟、厄他培南和左氧氟沙星的人源化暴露，以评估其对人类结果的转化价值。我们的数据支持这种鼠模型在人类 cUTI 中的转化效用，因为人源化暴露产生的微生物学结果与生物体的表型特征一致。
相似文献
1
Translational Efficacy of Humanized Exposures of Cefepime, Ertapenem, and Levofloxacin against Extended-Spectrum-β-Lactamase-Producing Escherichia coli in a Murine Model of Complicated Urinary Tract Infection.人源化暴露头孢吡肟、厄他培南和左氧氟沙星对产超广谱β-内酰胺酶大肠埃希菌在复杂性尿路感染小鼠模型中的转化功效。
Antimicrob Agents Chemother. 2017 Oct 24;61(11). doi: 10.1128/AAC.01329-17. Print 2017 Nov.
2
Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.哌拉西林-他唑巴坦、头孢吡肟和厄他培南治疗产超广谱β-内酰胺酶大肠埃希菌所致尿路感染的随机对照试验
BMC Infect Dis. 2017 Jun 7;17(1):404. doi: 10.1186/s12879-017-2502-x.
3
Aminoglycoside therapy for childhood urinary tract infection due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.氨基糖苷类药物治疗由产超广谱β-内酰胺酶的大肠埃希菌或肺炎克雷伯菌引起的儿童尿路感染。
BMC Infect Dis. 2015 Oct 13;15:414. doi: 10.1186/s12879-015-1153-z.
4
Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula.在不同接种量下测定头孢吡肟对产超广谱β-内酰胺酶大肠杆菌的体内药效学特征。
Antimicrob Agents Chemother. 2004 Jun;48(6):1941-7. doi: 10.1128/AAC.48.6.1941-1947.2004.
5
6
CTX-M-32 beta-lactamase-producing uropathogenic Escherichia coli isolated in Latin America.在拉丁美洲分离出的产CTX-M-32β-内酰胺酶的尿路致病性大肠杆菌。
J Infect Dev Ctries. 2013 May 13;7(5):432-5. doi: 10.3855/jidc.3488.
7
Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum β-lactamase.头孢西丁可作为携带 CTX-M-15 型超广谱β-内酰胺酶大肠埃希菌所致尿路感染的小鼠模型中的碳青霉烯类抗生素的替代药物。
Antimicrob Agents Chemother. 2012 Mar;56(3):1376-81. doi: 10.1128/AAC.06233-11. Epub 2012 Jan 3.
8
Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.医疗保健相关尿路感染中产超广谱β-内酰胺酶大肠埃希菌和肺炎克雷伯菌的抗菌药敏性：聚焦对磷霉素的敏感性
Int Urol Nephrol. 2015 Jul;47(7):1059-66. doi: 10.1007/s11255-015-1018-9. Epub 2015 May 31.
9
Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections.社区获得性尿路感染中产 ESBL 大肠埃希菌的阳性危险因素。
Clin Microbiol Infect. 2010 Feb;16(2):147-51. doi: 10.1111/j.1469-0691.2009.02941.x. Epub 2009 Aug 18.
10
Refractory vertebral osteomyelitis due to CTX-M-14-producing Escherichia coli at ertapenem treatment in a patient with a coexisting urinary tract infection caused by the same pathogen.厄他培南治疗合并由同一病原体引起的尿路感染患者时，发生产 CTX-M-14 的大肠埃希菌引起的难治性脊椎骨髓炎。
Int J Infect Dis. 2010 Sep;14 Suppl 3:e183-6. doi: 10.1016/j.ijid.2009.06.023. Epub 2009 Oct 1.
引用本文的文献
1
and activities of KSP-1007, a broad-spectrum inhibitor of serine- and metallo-β-lactamases, in combination with meropenem against carbapenem-resistant Gram-negative bacteria.以及丝氨酸和金属β-内酰胺酶的广谱抑制剂KSP-1007与美罗培南联合使用对耐碳青霉烯革兰氏阴性菌的活性。
Antimicrob Agents Chemother. 2024 Jun 5;68(6):e0160223. doi: 10.1128/aac.01602-23. Epub 2024 May 6.
2
Evaluation of Immunocompetent Urinary Tract Infected Balb/C Mouse Model For the Study of Antibiotic Resistance Development Using CFT073 Infection.利用CFT073感染评估用于研究抗生素耐药性发展的免疫活性尿路感染Balb/C小鼠模型。
Antibiotics (Basel). 2019 Sep 28;8(4):170. doi: 10.3390/antibiotics8040170.
3
Efficacy of Meropenem with a Novel Non-β-Lactam-β-Lactamase Inhibitor, Nacubactam, against Gram-Negative Organisms Exhibiting Various Resistance Mechanisms in a Murine Complicated Urinary Tract Infection Model.美罗培南联合新型非β-内酰胺类β-内酰胺酶抑制剂奈拉滨对抗具有多种耐药机制的革兰氏阴性菌在小鼠复杂性尿路感染模型中的疗效。
Antimicrob Agents Chemother. 2018 Aug 27;62(9). doi: 10.1128/AAC.02596-17. Print 2018 Sep.
4
Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in a Murine Model of Pyelonephritis.美罗培南-法硼巴坦对肾盂肾炎小鼠模型中碳青霉烯类耐药肠杆菌科的活性。
Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01439-17. Print 2018 Jan.
本文引用的文献
1
Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.哌拉西林-他唑巴坦、头孢吡肟和厄他培南治疗产超广谱β-内酰胺酶大肠埃希菌所致尿路感染的随机对照试验
BMC Infect Dis. 2017 Jun 7;17(1):404. doi: 10.1186/s12879-017-2502-x.
2
Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial.头孢洛扎/他唑巴坦与左氧氟沙星治疗由耐左氧氟沙星病原体引起的复杂性尿路感染（cUTIs）的疗效：ASPECT-cUTI试验结果
J Antimicrob Chemother. 2016 Jul;71(7):2014-21. doi: 10.1093/jac/dkw053. Epub 2016 Mar 18.
3
Efficacy of humanized high-dose meropenem, cefepime, and levofloxacin against Enterobacteriaceae isolates producing Verona integron-encoded metallo-β-lactamase (VIM) in a murine thigh infection model.人源化大剂量美罗培南、头孢吡肟和左氧氟沙星在小鼠大腿感染模型中对产维罗纳整合子编码金属β-内酰胺酶（VIM）的肠杆菌科分离株的疗效。
Antimicrob Agents Chemother. 2015 Nov;59(11):7145-7. doi: 10.1128/AAC.00794-15. Epub 2015 Sep 28.
4
Urinary tract infections: epidemiology, mechanisms of infection and treatment options.尿路感染：流行病学、感染机制及治疗选择
Nat Rev Microbiol. 2015 May;13(5):269-84. doi: 10.1038/nrmicro3432. Epub 2015 Apr 8.
5
In vivo activities of simulated human doses of cefepime and cefepime-AAI101 against multidrug-resistant Gram-negative Enterobacteriaceae.模拟人体剂量的头孢吡肟和头孢吡肟 - AAI101对多重耐药革兰氏阴性肠杆菌科细菌的体内活性。
Antimicrob Agents Chemother. 2015 May;59(5):2688-94. doi: 10.1128/AAC.00033-15. Epub 2015 Feb 23.
6
Clinical outcomes with ertapenem as a first-line treatment option of infections caused by extended-spectrum β-lactamase producing gram-negative bacteria.厄他培南作为产超广谱β-内酰胺酶革兰氏阴性菌感染一线治疗选择的临床结果。
Ann Pharmacother. 2012 Mar;46(3):347-52. doi: 10.1345/aph.1Q473. Epub 2012 Mar 6.
7
Levofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritis.左氧氟沙星治疗复杂性尿路感染和急性肾盂肾炎。
Ther Clin Risk Manag. 2008 Oct;4(5):843-53. doi: 10.2147/tcrm.s3426.
8
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.美罗培南和厄他培南在中性粒细胞减少小鼠大腿模型中对产超广谱β-内酰胺酶大肠埃希菌和肺炎克雷伯菌的杀菌活性。
Antimicrob Agents Chemother. 2007 Apr;51(4):1481-6. doi: 10.1128/AAC.00752-06. Epub 2007 Feb 5.
9
The bactericidal action of penicillin in vivo: the participation of the host, and the slow recovery of the surviving organisms.青霉素在体内的杀菌作用：宿主的参与及存活细菌的缓慢恢复
Ann Intern Med. 1950 Sep;33(3):544-71. doi: 10.7326/0003-4819-33-3-544.
Zotero 插件